Clinical Trials Logo

Vascular Diseases clinical trials

View clinical trials related to Vascular Diseases.

Filter by:

NCT ID: NCT01157949 Withdrawn - Clinical trials for Cardiac Allograft Vasculopathy

A Study to Compare the Effectiveness of a Drug That Suppresses the Immune System Called Thymoglobulin® in Preventing the Development of a Disease That Affects the Majority of Heart Transplant Recipients Called Cardiac Allograft Vasculopathy (CAV)

Start date: November 2010
Phase: Phase 3
Study type: Interventional

The purpose of this study is to test the hypothesis that administering Thymoglobulin® induction therapy early after transplant prevents the development of cardiac allograft vasculopathy (CAV). CAV accounts for a significant number of deaths in cardiac recipients after the first year of transplant. At 5 years post-transplant 30% of the deaths are due to CAV. With the exception of re-transplantation the available treatments for CAV are only effective at inhibiting its progression. CAV involves only the allograft and spares the native arteries, suggesting an immunologic basis for the disease. However, both immunological and non-immunological factors contribute to the development of CAV. The established immunological risk factors are recurrent rejection and humoral/antibody-mediated rejection (AMR). Non-immunological risk factors identified include preservation injury, the cause of donor death, donor graft ischemic time, and cytomegalovirus infection1. It is hypothesized that these factors increase the risk of developing CAV by causing early endothelial damage to the graft, which then could promote increased lymphocyte-endothelial interactions and the production of anti-endothelial antibodies2. The investigators hypothesized that Thymoglobulin induction therapy would prevent the development of CAV because its polyclonal nature allows Thymoglobulin to target all the potential mechanisms that contribute to the development of CAV—T-cell activation, B-cell activation, antibody formation, induction of tolerance, and modulation of lymphocyte-endothelium interactions3. Because the mechanism by which Thymoglobulin affects the immune system are still poorly understood, the investigators will also study how Thymoglobulin changes the immune system over time in the heart transplant recipient as a secondary objective.

NCT ID: NCT00751283 Withdrawn - Clinical trials for Peripheral Vascular Disease

Radiofrequency for the Treatment of Peripheral Vascular Occlusive Disease of the Lower Extremities

Start date: August 2007
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of the Minnow Medical GRST Peripheral Catheter System in the treatment of new lesions in the superficial femoral artery or the popliteal artery.

NCT ID: NCT00672698 Withdrawn - Clinical trials for PERIPHERAL VASCULAR DISEASES

Evaluation of Surgical Risk in Elderly Patients Submitted to Elective Surgery

Start date: November 2008
Phase: N/A
Study type: Observational

The purpose of this study is to establish the surgical risk factors and differences between different diseases in elderly patients submitted to elective surgery in our institution.

NCT ID: NCT00579241 Withdrawn - Clinical trials for Coronary Artery Disease

Detection of Ultrasound Contrast Signals in the Cerebral Circulation

Start date: April 27, 2006
Phase: N/A
Study type: Interventional

To Determine whether transcranial ultrasound can detect the presence of intravenously injected microbubbles used routinely for dobutamine stress echocardiography.

NCT ID: NCT00334724 Withdrawn - Hypertension Clinical Trials

Home Blood Pressure-guided Antihypertensive Intervention for Elderly (HBP-GUIDE) Study

Start date: October 2006
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine whether blood pressure control by home blood pressure monitoring exerts beneficial cardioprotective effects rather than by clinic blood pressure monitoring in elderly patients.